Principal Analyst, Datamonitor Healthcare
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Amanda Micklus
Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.
Merck & Co. signed a $1.66 billion deal to license Sutro Biopharma’s immune-modulating cytokine derivatives in oncology and autoimmune disease. Boston Scientific announced two acquisitions, Claret Medical in the embolic protection space, and Cryterion Medical, a cryoablation company. Biopharma and device financing slowed down in July.
Sanofi teamed up with Translate Bio in an $850 million mRNA vaccine/infectious disease deal. Novartis spun off the device assets of Alcon through a share buyback program worth $5 billion. Strong showings from FOPOs and IPOs boosted biopharma financing to $5.2 billion.
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.